Mount Tam Biotechnologies will first focus exclusively on its SLE clinical candidate, TAM-01, until it reaches later stage clinical trials. Mount Tam will leverage TAM-01 investment into additional autoimmune indications as it continues to develop. The second indication for TAM-01 will be identified by 2016 when screening efforts will begin. Mount Tam will expand to include Multiple Sclerosis with TAM-02 development by 2016.